Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab for Psychoses Possibly Caused by Synaptic Autoimmunity
NCT03971487Phase 2Recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- Oct 2019
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia and schizoaffective disorder comparing Ocrelizumab with Placebo (2 arms). Primary endpoint: Positive and Negative Syndrome Scale at 6 months. Started Oct 2019; status: recruiting.
02
Drugs
ocrelizumab
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT03971487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03971487.